SCHEMBL2072831

SCHEMBL2072831

Cc1[nH]nc(-c2[c]cccc2)c1C

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.34
AKT2 P31751 2/20 0.34
CHEK1 O14757 1/20 0.34
AURKA O14965 2/20 0.33
AURKB Q96GD4 2/20 0.33
KMT2A Q03164 4/20 0.33
MEN1 O00255 3/20 0.32
LMNA P02545 2/20 0.32
MAPT P10636 2/20 0.32
GPR55 Q9Y2T6 2/20 0.32
KDM4E B2RXH2 1/20 0.32
CNR1 P21554 1/20 0.32
TGFBR1 P36897 1/20 0.31
MAPK14 Q16539 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
HSP90AA1 P07900 1/20 0.31
HSP90AB1 P08238 1/20 0.31
ALDH1A1 P00352 1/20 0.30
MAPK1 P28482 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17183456 0.75 L3MBTL1 (0.55) AURKAAURKBLMNAMAPTKDM4E
SCHEMBL15227249 0.72 MAPK1 (0.52) DYRK1ACHEK1AURKAAURKBKMT2A
SCHEMBL3140348 0.71 IDO1 (0.56) AURKAKDM4EALDH1A1MAPK1
SCHEMBL11622606 0.71 AKT2 (0.53) AKT2CHEK1KMT2ALMNAMAPT
SCHEMBL3146090 0.68 PTGS1 (0.41) KMT2AMEN1LMNAMAPTHSP90AB1
SCHEMBL225083 0.68 PTGS1 (0.30)
SCHEMBL18304106 0.68 BRD4 (0.40) LMNAMAPTKDM4EALDH1A1SMN1; SMN2
SCHEMBL714994 0.67 CCR1 (0.56) KMT2AMEN1LMNAKDM4ETGFBR1
SCHEMBL12815956 0.66 CYP1A2 (0.31)
SCHEMBL115447 0.66 CYP3A4 (0.33) SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1828171-B1 HETEROCYCLE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS ANGELETTI P IST RICHERCHE BIO (IT) 2014-03-12 EP disclosed
US-7863294-B2 Heterocycle derivatives as histone deacetylase (HDAC) inhibitors INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2011-01-04 US disclosed
US-20090048228-A1 Heterocycle Derivatives As Histone Deacetylase (Hdac) Inhibitors MSD ITALIA S.R.L. (IT) 2009-02-19 US disclosed
EP-1828171-A2 HETEROCYCLE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 2007-09-05 EP disclosed
WO-2006061638-A2 HETEROCYCLE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048228-A1 Heterocycle Derivatives As Histone Deacetylase (Hdac) Inhibitors HDAC1, HDAC5, HDAC11 DYRK1A 3431/4885AKT2 2196/4885CHEK1 2136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.